FIELD: biotechnology; immunology; virology; genetics; molecular biology.
SUBSTANCE: isolated recombinant receptor-binding domain of glycoprotein S (hereinafter – RBD-S) of coronavirus type 2 causing severe acute respiratory syndrome (hereinafter – SARS-CoV-2 virus), as well as nucleic acid, which encodes RBD-S of SARS-CoV-2 virus are described.
EFFECT: invention expands the arsenal of means for the treatment or prevention of a coronavirus infection.
5 cl, 10 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
Authors
Dates
2022-11-11—Published
2020-08-28—Filed